Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)

PHASE3CompletedINTERVENTIONAL
Enrollment

187

Participants

Timeline

Start Date

November 6, 2019

Primary Completion Date

October 28, 2021

Study Completion Date

October 28, 2021

Conditions
Rett Syndrome
Interventions
DRUG

Trofinetide

Trofinetide solution administered based on the subject's weight at Baseline, twice daily for 12 weeks

OTHER

Placebo

Trofinetide placebo solution administered based on the subject's weight at Baseline, twice daily for 12 weeks

Trial Locations (21)

10467

Montefiore Medical Center, Children's Hospital at Montefiore, The Bronx

19104

Children's Hospital of Philadelphia, Philadelphia

21205

Kennedy Krieger Institute - Clinical Trials Unit, Baltimore

27599

The University of North Carolina at Chapel Hill, Chapel Hill

29646

Greenwood Genetic Center, Greenwood

30322

Emory Genetics Clinical Trial Center, Atlanta

33606

Children Medical Services, Tampa

35233

University of Alabama at Birmingham, Birmingham

37232

Vanderbilt University Medical Center, Nashville

44195

Cleveland Clinic, Cleveland

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

55101

Gillette Children's Specialty Healthcare, Saint Paul

60612

Rush University Children's Hospital, Chicago

63110

Washington University School of Medicine, St Louis

77030

Texas Children's Hospital, Houston

80042

Children's Hospital Colorado, Aurora

85012

Translational Gemomics Research Institute (TGen), Phoenix

92093

University of California, San Diego, La Jolla

95817

UC Davis MIND Institute, Sacramento

98105

Seattle Children's, Seattle

02115

Boston Children's Hospital Harvard Medical School, Boston

Sponsors
All Listed Sponsors
lead

ACADIA Pharmaceuticals Inc.

INDUSTRY